Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Bibhuti B DasFrank SchollBreanna VandaleMaryanne ChrisantPublished in: Cardiology in the young (2018)
The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.
Keyphrases
- heart failure
- ejection fraction
- angiotensin converting enzyme
- intensive care unit
- emergency department
- left ventricular
- angiotensin ii
- acute heart failure
- cardiac resynchronization therapy
- atrial fibrillation
- human health
- young adults
- randomized controlled trial
- study protocol
- coronary artery disease
- risk factors
- climate change
- clinical evaluation